Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2013 Aug 1;23(15):4308-14. doi: 10.1016/j.bmcl.2013.05.099. Epub 2013 Jun 10.

Discovery of triazines as potent, selective and orally active PDE4 inhibitors.

Author information

1
BioCrea GmbH, Meissner Strasse 191, 01445 Radebeul, Germany. rainer.gewald@telecolumbus.net

Abstract

Expanding on HTS hit 4 afforded a series of [1,3,5]triazine derivatives as novel PDE4 inhibitors. The SAR development and optimization process with the emphasis on ligand efficiency and physicochemical properties led to the discovery of compound 44 as a potent, selective and orally active PDE4 inhibitor.

PMID:
23806553
DOI:
10.1016/j.bmcl.2013.05.099
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center